Profil
Frederique Lafosse currently works at EnginZyme AB, as Director.
Aktive Positionen von Frederique Lafosse
| Unternehmen | Position | Beginn |
|---|---|---|
EnginZyme AB
 EnginZyme AB BiotechnologyHealth Technology EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
EnginZyme AB
EnginZyme AB BiotechnologyHealth Technology EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014. | Health Technology |
